Unbuzzd Wellness Investor Webinar to Showcase Alcohol Metabolism Beverage Investment Opportunity

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that its licensee Unbuzzd Wellness will host an Investor Webinar on September 16, 2025, featuring key executives who will outline the current Reg D 506(c) investment opportunity. The webinar will review clinical data and highlight strategies to accelerate direct-to-consumer, distributor, and retail sales of unbuzzd(TM), the scientifically proven beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

The event gains importance as it represents a strategic opportunity for investors to participate in the growing market for alcohol-related wellness products. Quantum BioPharma retains significant financial interest in Unbuzzd Wellness, owning 20.11% of the company as of March 31, 2025, and receiving royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. This financial structure demonstrates the long-term value proposition for both companies and potential investors.

The webinar's focus on clinical data validation is crucial, as it addresses the scientific credibility of unbuzzd(TM) in a market where many similar products lack rigorous testing. The participation of Medical Director Dr. Eric Hoskins adds medical authority to the presentation, potentially increasing investor confidence in the product's efficacy and safety profile. The strategic emphasis on accelerating sales across multiple channels indicates a comprehensive market penetration approach that could significantly impact revenue generation.

For the latest news and updates relating to QNTM, investors can access the company's newsroom at https://ibn.fm/QNTM. The broader context of this announcement matters because it represents the convergence of biopharmaceutical innovation with consumer wellness products, creating new investment opportunities in the rapidly expanding health and wellness sector. The retention of pharmaceutical development rights by Quantum BioPharma suggests potential future expansion into medical applications, adding another layer of long-term value to the investment proposition.